Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/2366
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAhuja, Suraj-
dc.date.accessioned2024-05-12T06:50:19Z-
dc.date.available2024-05-12T06:50:19Z-
dc.date.issued2023-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/2366-
dc.language.isoen_USen_US
dc.publisherIIHMR Universityen_US
dc.subjectPharmaceuticalen_US
dc.subjectCase Studyen_US
dc.subjectDrug Price Control Organization'sen_US
dc.subjectHealthcareen_US
dc.subjectCost-Effectivenessen_US
dc.subjectHealthcare Cost Implicationsen_US
dc.title"Comparative Analysis of Ceftazidime-Avibactam Brands: Evaluating Price, Potency, and Cost-Effectiveness for Enhanced Patient Outcomes and Affordability" and "Assessing the Healthcare Cost Implications of Drug Price Control Organization's (DPCO) Decision: A Case Study on Meropenem Price Ceiling “en_US
dc.typeSummer Reporten_US
dc.guideSharma, Rahulen_US
dc.organizationnameMedanta - The Medicity, Gurugramen_US
Appears in Collections:2023

Files in This Item:
File Description SizeFormat 
Suraj-c.pdfCertificate521.47 kBAdobe PDF Preview PDFDownload
Suraj-p.pdfPresentation2.09 MBAdobe PDF Preview PDFDownload
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.